Celyad Oncology SA 

Celyad Oncology SA is a clinical-stage biopharmaceutical entity dedicated to the discovery and advancement of chimeric antigen receptor T (CAR-T) cell therapies for cancer treatment. Its prominent clinical programs include CYAD-101, an allogeneic CAR-T candidate in a Phase 1b trial for metastatic colorectal cancer. Another significant asset is CYAD-211, an allogeneic CAR-T therapy based on short hairpin RNA (shRNA), currently undergoing Phase 1 evaluation for relapsed/refractory multiple myeloma. Additionally, CYAD-02, an autologous CAR-T candidate, is in Phase 1 trials for individuals with relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. Within its preclinical pipeline, the company is developing CYAD-203, a non-gene-edited allogeneic CAR-T candidate engineered to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for potential application in solid tumors. Celyad Oncology has established key collaborations, including a licensing agreement with Novartis International AG concerning U.S. patents for allogeneic CAR-T cells. It also maintains a research and development partnership, alongside licensing agreements, with Horizon Discovery Group plc to utilize their shRNA technology in creating a novel non-gene-edited allogeneic platform. Founded in 2004 as Celyad SA, the company rebranded to Celyad Oncology SA in June 2020 and is headquartered in Mont-Saint-Guibert, Belgium.